ロード中...
Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol
Overexpression and activation of the Epidermal Growth Factor Receptor (EGFR) have been linked to poor prognosis in several human cancers. Cetuximab is a monoclonal antibody against EGFR, that is used for the treatment in head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer....
保存先:
| 出版年: | Mol Cancer Ther |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5752575/ https://ncbi.nlm.nih.gov/pubmed/29054984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0384 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|